Clinical Trial Detail

NCT ID NCT03332589
Title E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Spirita Oncology, LLC
Indications

melanoma

Therapies

Dabrafenib + E6201

E6201

Age Groups: adult senior

Additional content available in CKB BOOST